Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Samuel Wickline
Washington University, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Acuplaq, Inc.
Other : IP Rights Through Awardee Inst
Based on Washington University’s (WU) Research COI Policy and the Procedures for Determining and Managing Research Financial Conflicts of Interests, WU determined Dr. Wickline's personal financial relationship with Acuplaq, Inc., related to the above referenced research creates a financial conflict of interest due to the following reasons:
•Dr. Wickline's personal financial relationship is directly related to the study because the studies are utilizing and evaluating his Intellectual Property, “Nanoparticles Functionalized with Small Molecule Inhibitors of Coagulation”, which is licensed by Acuplaq
•If the results of the study are favorable it could impact the value of the IP, which could also increase the value of the entity
•Dr. Wickline's role as the PI of the study, in designing the study, collecting and analyzing data, reporting the results, oversight of the research, supervising individuals involved with the research could directly affect the outcome of the study
ANTI-INFLAMMATORY THERAPEUTICS FOR CARDIOVASCULAR DISEASE
Inflammation in atherosclerotic plaque is a key promoter of acute vascular syndromes (i.e., thrombosis). The theme of this proposal is the development and testing of nanoparticle based approaches for the diagnosis and therapy of cardiovascular diseases to detect, treat, and monitor unstable atheroma. We seek to develop new molecularly targeted nanotherapies that interrupt inflammatory signaling molecules with the clinical goal of reducing the propensity toward thrombosis in acute vascular syndromes. These will be tested in vivo in mouse models as single agent and combination therapies.
Filed on April 23, 2013.
Tell us what you know about Samuel Wickline's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Samuel Wickline filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq, Inc. | $0 - $4,999 |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq Inc. | $0 - $4,999 |
| Samuel Wickline | Washington University | Conflict of Interest | Entropy Vision, LLC | $0 - $4,999 |
| Samuel Wickline | University of South Florida | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq, Inc. | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq Inc. | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq Inc. | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Entropy Vision, LLC | Value cannot be readily determined |
| Samuel Wickline | University of South Florida | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | University of South Florida | Conflict of Interest | AcuPlaq, LLC | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | University of South Florida | Conflict of Interest | AcuPlaq, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.